Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/39947
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Holdsworth S.R. | en |
dc.contributor.author | Gan P.-Y. | en |
dc.contributor.author | Kitching A.R. | en |
dc.date.accessioned | 2021-05-14T13:39:35Z | en |
dc.date.available | 2021-05-14T13:39:35Z | en |
dc.date.copyright | 2016 | en |
dc.date.created | 20160311 | en |
dc.date.issued | 2016-03-11 | en |
dc.identifier.citation | Nature Reviews Nephrology. 12 (4) (pp 217-231), 2016. Date of Publication: 01 Apr 2016. | en |
dc.identifier.issn | 1759-5061 | en |
dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/39947 | en |
dc.description.abstract | Biological therapeutics (biologics) that target autoimmune responses and inflammatory injury pathways have a marked beneficial impact on the management of many chronic diseases, including rheumatoid arthritis, psoriasis, inflammatory bowel disease, and ankylosing spondylitis. Accumulating data suggest that a growing number of renal diseases result from autoimmune injury-including lupus nephritis, IgA nephropathy, anti-neutrophil cytoplasmic antibody-associated glomerulonephritis, autoimmune (formerly idiopathic) membranous nephropathy, anti-glomerular basement membrane glomerulonephritis, and C3 nephropathy-and one can speculate that biologics might also be applicable to these diseases. As many autoimmune renal diseases are relatively uncommon, with long natural histories and diverse outcomes, clinical trials that aim to validate potentially useful biologics are difficult to design and/or perform. Some excellent consortia are undertaking cohort studies and clinical trials, but more multicentre international collaborations are needed to advance the introduction of new biologics to patients with autoimmune renal disorders. This Review discusses the key molecules that direct injurious inflammation and the biologics that are available to modulate them. The opportunities and challenges for the introduction of relevant biologics into treatment protocols for autoimmune renal diseases are also discussed.Copyright © 2016 Macmillan Publishers Limited. | en |
dc.language | English | en |
dc.language | en | en |
dc.publisher | Nature Publishing Group (Houndmills, Basingstoke, Hampshire RG21 6XS, United Kingdom) | en |
dc.relation.ispartof | Nature Reviews Nephrology | en |
dc.title | Biologics for the treatment of autoimmune renal diseases. | en |
dc.type | Article | en |
dc.identifier.doi | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1038/nrneph.2016.18 | en |
dc.publisher.place | United Kingdom | en |
dc.identifier.pubmedid | 26949177 [http://www.ncbi.nlm.nih.gov/pubmed/?term=26949177] | en |
dc.identifier.source | 608872906 | en |
dc.identifier.institution | (Holdsworth, Gan, Kitching) Department of Medicine, Centre for Inflammatory Diseases, Monash University, Monash, VIC 3800, Australia (Holdsworth, Kitching) Department of Nephrology, Monash Health, 246 Clayton Road, Clayton, Melbourne, VIC 3168, Australia | en |
dc.description.address | S.R. Holdsworth, Department of Medicine, Centre for Inflammatory Diseases, Monash University, Monash, VIC 3800, Australia. E-mail: stephen.holdsworth@monash.edu | en |
dc.description.publicationstatus | Embase | en |
dc.rights.statement | Copyright 2016 Elsevier B.V., All rights reserved. | en |
dc.identifier.authoremail | Holdsworth S.R.; stephen.holdsworth@monash.edu | en |
item.cerifentitytype | Publications | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.openairetype | Article | - |
crisitem.author.dept | Immunology and Allergy | - |
crisitem.author.dept | Nephrology | - |
Appears in Collections: | Articles |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.